

Collection of data on the use of a VWF/FVIII concentrate (wilate®) in all clinical applications in von Willebrand disease

Submission date 19/01/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 09/02/2022	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 27/05/2025	Condition category Haematological Disorders	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Von Willebrand disease (VWD) is a blood disorder in which the blood does not clot properly due to low levels of the clotting protein von Willebrand factor (VWF). Medicines such as wilate can be used to replace the missing factor. The aim of this study is to determinate the effectiveness and tolerability of wilate in the prophylaxis (prevention) and treatment of bleeding as well as in surgical interventions under everyday clinical conditions.

Who can participate?

Patients with VWD requiring treatment with VWF-containing product (wilate)

What does the study involve?

The routine treatment of VWD patients will be documented, including all treatments with Wilate, any bleeding episodes, surgical interventions and optional data on quality of life and joint health.

What are the possible benefits and risks of participating?

All information collected in the course of the treatment with wilate will add knowledge on the use of wilate and treatment of the VWD under routine conditions. There are no risks arising from participation.

Where is the study run from?

Gerinnungszentrum Rhein-Ruhr (GZRR) (Germany)

When is the study starting and how long is it expected to run for?

January 2020 to May 2025

Who is funding the study?

Octapharma GmbH (Germany)

Who is the main contact?
Dr Susanne Seeger
susanne.seeger@octapharma.com

Contact information

Type(s)
Scientific

Contact name
Dr Susanne Seeger

Contact details
Elisabeth-Selbert-Str. 11
Langenfeld
Germany
40764
+49 (0)2173917131
susanne.seeger@octapharma.com

Additional identifiers

Protocol serial number
WIL-34

Study information

Scientific Title
Non-interventional study to capture data on the use of a VWF/FVIII concentrate (wilate®) in all clinical settings of von Willebrand disease including health-related quality of life

Acronym
wilate-NEWS

Study objectives
Wilate is efficacious and safe for the treatment of von Willebrand's disease in clinical practice.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved 28/09/2020, Ethics Committee of Medical Association of North Rhine (Ärztchamber Nordrhein, Tersteegenstraße 9, 40474 Düsseldorf, Germany; +49 (0)211 4302 2272; ethik@aekno.de), ref: 2020260

Study design
Open prospective multi-centre national non-interventional study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Von Willebrand disease (VWD)

Interventions

wilate-NEWS is a non-interventional study for which the routine treatment of VWD patients on prophylaxis or on-demand treatment is documented. All treatments occurring with wilate, any bleeding episodes occurring or surgical procedures are carefully documented. Additionally, a joint score (HJHS), quality of life questionnaire (SF-36) and/or a pictorial blood assessment chart (PBAC) can be documented on an optional basis. The observation period of each patient is not fixed. Follow-up is planned at regular intervals (every 6 months) after the inclusion of the patients.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

wilate®

Primary outcome(s)

Percentage of haemostatic efficacy ratings of "excellent" and "good" for bleeding treatments and surgical interventions, as well as the annual bleeding rate in prophylactically treated patients, measured at the end of the study. According to the study protocol, efficacy is rated by the treating physicians for every bleeding event treated with Wilate and surgery respectively treated with Wilate on a 4-point Likert scale (excellent, good, moderate, none).

Key secondary outcome(s)

1. Safety assessed using the number of patients experiencing at least one adverse drug reaction (ADR) measured at the end of the study
2. Calculation of the VWF dose/kg body weight per injection and calculation of the duration of use in the different treatment options (prophylaxis, bleeding treatment, surgical intervention), depending on the VWD type or severity of bleeding or intervention, at the end of the study
3. Health-related quality of life measured optionally half-yearly using SF-36 during treatment with Wilate, including a comparison between types of VWD and between female and male patients - as far as case numbers allow
4. Comparison of joint status determined optionally half-yearly using the Haemophilia Joint Health Score (HJHS) and annualised bleeding rate, taking into account the treatment mode as well as the VWD type (as far as the case numbers allow), at the end of the study
5. PBAC (Pictorial Blood Assessment Chart) scores in relation to treatment regimen and dosages at the end of the study

Completion date

31/05/2030

Eligibility

Key inclusion criteria

1. The patient has congenital or acquired Von Willebrand disease (VWD) and requires injections with VWF-containing concentrate (wilate)
2. With a positive bleeding history, other possible causes have been excluded

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

All

Sex

All

Key exclusion criteria

1. Patients with known contraindications as specified in the Summary of Product Characteristics (SPC)
2. The patient could actually be treated with DDAVP (Desmopressin Acetate)
3. The patient has a von Willebrand factor activity over 70% and there are no findings manifesting the VWD diagnosis

Date of first enrolment

01/06/2020

Date of final enrolment

31/05/2025

Locations

Countries of recruitment

Germany

Study participating centre

Gerinnungszentrum Rhein-Ruhr (GZRR)

Duisburg

Germany

47051

Sponsor information

Organisation

Octapharma GmbH

Funder(s)**Funder type**

Other

Funder Name

Investigator initiated and funded

Results and Publications**Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date